Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM
New York, Jan 23, 2026, 15:38 EST — Regular session Gilead Sciences shares climbed $4.59, or 3.5%, to $135.73 in Friday afternoon trading, building on a strong two-day surge and hitting new highs. The stock started the day at $131.26 and fluctuated between $130.65 and $136.26, with roughly 8.8 million shares traded. This week, Gilead updated investors after The New England Journal of Medicine released full Phase 3 data on Trodelvy combined with Merck’s Keytruda for first-line PD-L1-positive metastatic triple-negative breast cancer. The company reported the combo cut the risk of disease progression or death by 35% compared to Keytruda